[1]夏维波.骨质疏松症防治中的难点和应对[J].国际内分泌代谢杂志,2022,42(03):165-169.[doi:10.3760/cma.j.cn121383-20220406-04011]
 Xia Weibo..Difficulties and countermeasures in prevention and treatment of osteoporosis[J].International Journal of Endocrinology and Metabolism,2022,42(03):165-169.[doi:10.3760/cma.j.cn121383-20220406-04011]
点击复制

骨质疏松症防治中的难点和应对()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年03期
页码:
165-169
栏目:
述评
出版日期:
2022-05-20

文章信息/Info

Title:
Difficulties and countermeasures in prevention and treatment of osteoporosis
作者:
夏维波
中国医学科学院 北京协和医学院 北京协和医院内分泌科,国家卫生健康委员会内分泌重点实验室 100730
Author(s):
Xia Weibo.
Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical Hospital,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
DOI:
10.3760/cma.j.cn121383-20220406-04011

参考文献/References:

[1] Consensus development conference:diagnosis,prophylaxis,and treatment of osteoporosis[J].Am J Med,1993,94(6):646-650.DOI:10.1016/0002-9343(93)90218-e.
[2] 第七次全国人口普查公报[1](第五号)——人口年龄构成情况[EB/OL].[2021-05-11].http://www.stats.gov.cn/ztjc/zdtjgz/zgrkpc/dqcrkpc/ggl/202105/t20210519_1817698.html.
[3] 中国疾病预防控制中心慢性非传染性疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查报告(2018)[M].北京:人民卫生出版社,2021.
[4] Wang L,Yu W,Yin X,et al.Prevalence of osteoporosis and fracture in China:the China osteoporosis prevalence study[J].JAMA Netw Open,2021,4(8):e2121106.DOI:10.1001/ jamanetworkopen.2021.21106.
[5] Zeng Q,Li N,Wang Q,et al.The prevalence of osteoporosis in China,a nationwide,multicent er DXA survey[J].J Bone Miner Res,2019.34(10):1789-1797.DOI:10.1002/jbmr.3757.
[6] Xu L,Lu A,Zhao X,et al.Very low rates of hip fracture in Beijing,people's republic of China the Beijing osteoporosis project[J].Am J Epidemiol,1996,144(9):901-907.DOI:10.1093/oxford journals.aje.a009024.
[7] Xia WB,He SL,Xu L,et al.Rapidly increasing rates of hip fracture in Beijing,China[J].J Bone Miner Res,2012,27(1):125-129.DOI:10.1002/jbmr.519.
[8] Zhang C,Feng J,Wang S,et al.Incidence of and trends in hip fracture among adults in urban China:A nationwide retrospective cohort study[J].PLoS Med,2020,17(8):e1003180.DOI:10.1371/journal.pmed.1003180.
[9] Ling X,Cummings SR,Mingwei Q,et al.Vertebral fractures in Beijing,China:the Beijing Osteoporosis Project[J].J Bone Miner Res,2000,15(10):2019-25.DOI:10.1359/jbmr.2000.15.10.2019.
[10] Cui L,Chen L,Xia W,et al.Vertebral fracture in postmenopausal Chinese women:a population-based study[J].Osteoporos Int,2017,28(9):2583-2590.DOI:10.1007/s00198-017-4085-1.
[11] Gao C,Xu Y,Li L,et al.Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai[J].Chin Med J(Engl),2019,132(14):1749-1751.DOI:10.1097/CM9.0000000000000332.
[12] Keene GS,Parker MJ,Pryor GA.Mortality and morbidity after hip fractures[J].BMJ,1993,307(6914):1248-1250.DOI:10.1136/bmj.307.6914.1248.
[13] Osnes EK,Lofthus CM,Meyer HE,et al.Consequences of hip fracture on activities of daily life and residential needs[J].Osteoporos Int,2004,15(7):567-574.DOI:10.1007/s00198-003-1583-0.
[14] Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.DOI:10.1007/s00198-015-3093-2.
[15] 国务院办公厅关于印发中国防治慢性病中长期规划(2017—2025年)的通知[EB/OL].[2017-02-14].http://www.gov.cn/zhengce/content/2017-02/14/content_5167886.htm.
[16] 关于印发全民健康生活方式行动方案(2017—2025年)的通知[EB/OL].[2017-04-27].http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=e73c1934c7f84c709e445f01 bf832b17.
[17] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-444.DOI:10.3969/j.issn.1674-2591.2017.05.002.
[18] Majumdar SR,Kim N,Colman I,et al.Incidental vertebral fractures discovered with chest radiography in the emergency department:prevalence,recognition,and osteoporosis management in a cohort of elderly patients[J].Arch Intern Med,2005,165(8):905-909.DOI:10.1001/archinte.165.8.905.
[19] 余卫,姚金鹏,林强,等.胸侧位像椎体压缩骨折诊断忽视原因浅析[J].中华放射学杂志,2010,44(5):504-507.DOI:10.3760/cma.j.issn.1005-1201.2010.05.013.
[20] Siris ES,Adler R,Bilezikian J,et al.The clinical diagnosis of osteoporosis:a position statement from the National Bone Health Alliance Working Group[J].Osteoporos Int,2014,25(5):1439-1443.DOI:10.1007/s00198-014-2655-z.
[21] Kanis JA,Cooper C,Rizzoli R,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int,2019,30(1):3-44.DOI:10.1007/s00198-018-4704-5.
[22] Liu S,Chen R,Ding N,et al.Setting the new FRAX reference threshold without bone mineral density in Chinese postmenopausal women[J].J Endocrinol Invest,2021,44(2):347-352.DOI:10.1007/s40618-020-01315-4.
[23] Cui L,He T,Jiang Y,et al.Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China:a cost-effectiveness analysis based on real-world data[J].Osteoporos Int,2020,31(2):307-316.DOI:10.1007/s00198-019-05173-6.
[24] van Geel TA,van Helden S,Geusens PP,et al.Clinical subsequent fractures cluster in time after first fractures[J].Ann Rheum Dis,2009,68(1):99-102.DOI:10.1136/ard.2008.092775.
[25] Kanis JA,Cooper C,Rizzoli R,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int,2019,30(1):3-44.DOI:10.1007/s00198-018-4704-5.
[26] Kendler DLMarin F,Zerbini CAF,et al.Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis(VERO):a multicentre,double-blind,double-dummy,randomised controlled trial[J].Lancet,2018,391(10117):230-240.DOI:10.1016/S0140-6736(17)32137-2.
[27] Saag KG,Petersen J,Brandi ML,et al.Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.DOI:10.1056/NEJMoa1708322.
[28] Akesson K,Marsh D,Mitchell PJ,et al.Capture the fracture:a best practice framework and global campaign to break the fragility fracture cycle[J].Osteoporos Int,2013,24(8):2135-2152.DOI:10.1007/s00198-013-2348-z.
[29] 夏维波.开展“骨折联络服务”,减少再发骨折[J].中华骨质疏松和骨矿盐疾病杂志,2016,9(1):1-6.DOI:10.3969/j.issn.1674-2591.2016.01.001.

备注/Memo

备注/Memo:
通信作者:夏维波,Email:xiaweibo8301@163.com
更新日期/Last Update: 2022-05-10